ASSURE S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics.
作者信息
Porta Camillo, Chiellino Silvia
机构信息
Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy; ; Italian Group of Onco-Nephrology (Gruppo Italiano di Oncologia Nefrologica/GION), Pavia, Italy.
Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy.
出版信息
Ann Transl Med. 2016 Oct;4(Suppl 1):S14. doi: 10.21037/atm.2016.10.45.
Abstract
摘要
相似文献
1
ASSURE S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics.
Ann Transl Med. 2016 Oct;4(Suppl 1):S14. doi: 10.21037/atm.2016.10.45.
2
Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
J Urol. 2018 Jan;199(1):43-52. doi: 10.1016/j.juro.2017.04.092. Epub 2017 May 4.
3
Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature.
Clin Genitourin Cancer. 2018 Jun;16(3):176-183. doi: 10.1016/j.clgc.2018.01.003. Epub 2018 Feb 2.
4
Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database.
Eur J Surg Oncol. 2016 May;42(5):744-50. doi: 10.1016/j.ejso.2016.01.009. Epub 2016 Jan 22.
5
Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma.
Cancer. 2012 Sep 15;118(18):4412-20. doi: 10.1002/cncr.26695. Epub 2012 Jan 3.
6
Adjuvant therapy in renal cell carcinoma: the perspective of urologists.
Int J Clin Oncol. 2019 Jun;24(6):694-697. doi: 10.1007/s10147-019-01398-x. Epub 2019 Feb 13.
7
Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials.
Ann Oncol. 2017 Apr 1;28(4):898-899. doi: 10.1093/annonc/mdw667.
8
Adjuvant therapy after nephrectomy for renal cell carcinoma.
Asia Pac J Clin Oncol. 2018 Nov;14 Suppl 5:33-36. doi: 10.1111/ajco.13056.
9
Adjuvant therapy for high-risk renal cell carcinoma after nephrectomy how many trials are positive? Only one or more than one.
Asia Pac J Clin Oncol. 2020 Sep;16 Suppl 3:12-17. doi: 10.1111/ajco.13314.
10
A new approach to kidney wait-list management in the kidney allocation system era: Pilot implementation and evaluation.
Clin Transplant. 2018 Nov;32(11):e13406. doi: 10.1111/ctr.13406. Epub 2018 Oct 15.
引用本文的文献
1
Endoplasmic Reticulum Stress in Renal Cell Carcinoma.
Int J Mol Sci. 2023 Mar 3;24(5):4914. doi: 10.3390/ijms24054914.
2
Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology.
Cancers (Basel). 2023 Feb 23;15(5):1433. doi: 10.3390/cancers15051433.
3
Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts.
Curr Oncol. 2018 Oct;25(5):e444-e453. doi: 10.3747/co.25.3865. Epub 2018 Oct 31.
4
Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.
Ther Adv Urol. 2017 Jun 29;9(8):195-207. doi: 10.1177/1756287217713902. eCollection 2017 Aug.
5
Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.
J Urol. 2018 Jan;199(1):53-59. doi: 10.1016/j.juro.2017.07.042. Epub 2017 Jul 18.
本文引用的文献
1
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
N Engl J Med. 2016 Dec 8;375(23):2246-2254. doi: 10.1056/NEJMoa1611406. Epub 2016 Oct 9.
2
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Lancet. 2016 May 14;387(10032):2008-16. doi: 10.1016/S0140-6736(16)00559-6. Epub 2016 Mar 9.
3
A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies.
Lancet Oncol. 2015 Jun;16(6):676-85. doi: 10.1016/S1470-2045(15)70167-1. Epub 2015 May 12.
4
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.
Target Oncol. 2015 Dec;10(4):517-22. doi: 10.1007/s11523-014-0356-3. Epub 2015 Jan 6.
5
Adjuvant therapy for renal cell carcinoma: past, present, and future.
Oncologist. 2014 Aug;19(8):851-9. doi: 10.1634/theoncologist.2014-0105. Epub 2014 Jun 26.
6
The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters.
Am J Surg Pathol. 2013 Oct;37(10):1490-504. doi: 10.1097/PAS.0b013e318299f0fb.
7
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents.
Clin Genitourin Cancer. 2013 Dec;11(4):471-6. doi: 10.1016/j.clgc.2013.04.018. Epub 2013 Jun 28.
8
Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
Lancet Oncol. 2013 Feb;14(2):159-167. doi: 10.1016/S1470-2045(12)70584-3. Epub 2013 Jan 16.
9
The VHL/HIF axis in clear cell renal carcinoma.
Semin Cancer Biol. 2013 Feb;23(1):18-25. doi: 10.1016/j.semcancer.2012.06.001. Epub 2012 Jun 13.
10
Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
J Clin Invest. 2006 Oct;116(10):2610-21. doi: 10.1172/JCI24612.
Zotero 插件